$FATE News

Piper Sandler Reiterates Overweight on Fate Therapeutics, Raises Price Target to $8

Wells Fargo Maintains Equal-Weight on Fate Therapeutics, Raises Price Target to $3.5

Wedbush Reiterates Outperform on Fate Therapeutics, Maintains $7 Price Target

Fate Therapeutics Highlights Initiation Of And Treatment Of First Patient In RECLAIM-LN, Phase 2 Potentially Registrational Clinical Trial Of FT819 In Patients With Refractory Moderate-To-Severe SLE With Lupus Nephritis

Fate Therapeutics Q2 EPS $(0.25) Beats $(0.27) Estimate, Sales $2.082M Beat $1.366M Estimate

FATE Stock Jumps 6% As FDA Greenlights Moving Cell Therapy To Clinical Trials

Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate

CORRECTION: Fate Therapeutics' Receives FDA Clearance For Its Investigational New Drug Application For FT839; Enrollment In Phase 1/2 Trial Anticipated In H2 2026

Fate Therapeutics: There Is A Bull Case, But It's Going To Take Time To Develop (Rating Downgrade)

Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting

Fate Therapeutics To Demonstrate Data On Its CAR T-cell Product Candidate FT819 At International Society For Stem Cell Research 2026 Annual Meeting

Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences

Fate Therapeutics: FT819 Progress Keeps My Bull Case Alive

Fate Therapeutics Appoints Laura Hamill to Board of Directors

H.C. Reiterates “Buy” Rating On Fate Therapeutics (FATE) With $7 PT

HC Wainwright & Co. Reiterates Buy on Fate Therapeutics, Maintains $7 Price Target

Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting

Fate Therapeutics Showcases Data Featuring Its CAR T-Cell Programs At European Congress Of Rheumatology

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Fate Therapeutics Showcases Clinical Data for FT836 at the American Society of Cancer Oncology Annual Meeting